Today's quarterly results came in inline with forecasts or perhaps a little conservative imo.
It's another step in the right direction for Volpara and is setting up nicely for 2020.
The key information for me on the conference call was the merger seems to have gone smoothly and benefits for this should become evident in 2020.
The pending news regarding the 10 year clinical trials should create strong sales opportunities for Volpara density scanning software. Also, the FDA news is expected that could create significant sales growth. Both these are expected this year imo.
The CFO mentioned Net Cash Flow should reduce next year. Plenty of cash in the bank - $40m.
Its an exciting HealthTech company where management are heavily invested with us. It's the right sector at the right time.
VHT Price at posting:
$1.66 Sentiment: Buy Disclosure: Held
